Bavarian Nordic (CPSE:BAVA) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

BAVA Stoklara Genel Bakış

Bavarian Nordic A/S hayat kurtaran aşılar geliştirmekte, üretmekte ve ticarileştirmektedir.

BAVA temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	1/6
Geçmiş Performans	1/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 80.2% daha düşük bir oranda işlem görüyor

Kazançların yılda 9.69% oranında artması öngörülüyor

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Kar marjları (11.6%) geçen yılın (19.5%) altında

Son 3 ayda dalgalı hisse senedi fiyatı

Finansal sonuçları etkileyen büyük tek seferlik kalemler

Son 3 ayda önemli miktarda içeriden satış gerçekleşti

Bavarian Nordic A/S Rakipler

Genmab

CPSE:GMAB

DKK 99.3b

PeptiDream

TSE:4587

JP¥382.4b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.5b

ALK-Abelló

CPSE:ALK B

DKK 38.2b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Bavarian Nordic
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	DKK 217.10
52 Haftanın En Yüksek Seviyesi	DKK 300.00
52 Haftanın En Düşük Seviyesi	DKK 125.55
Beta	1.54
11 Aylık Değişim	-10.66%
3 Aylık Değişim	17.35%
1 Yıllık Değişim	65.92%
33 Yıllık Değişim	-30.08%
5 Yıllık Değişim	34.26%
Halka arzdan bu yana değişim	-14.86%

Son Haberler & Güncellemeler

Recent updates

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Aug 26

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Aug 25

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Aug 09

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Jul 11

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

May 12

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 09

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Feb 26

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Jan 03

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Dec 10

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Nov 15

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Aug 17

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 19

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Jan 03

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Sep 15

Hissedar Getirileri

	BAVA	DK Biotechs	DK Pazar
7D	2.9%	0.3%	-0.9%
1Y	65.9%	6.8%	19.7%

Getiri vs. Endüstri: BAVA geçen yıl % -5.1 oranında getiri sağlayan Danish Biotechs sektörünü aştı.

Getiri vs Piyasa: BAVA geçen yıl % 21.8 oranında getiri sağlayan Danish Piyasasını aştı.

Fiyat Oynaklığı

Is BAVA's price volatile compared to industry and market?
BAVA volatility
BAVA Average Weekly Movement	8.9%
Biotechs Industry Average Movement	7.9%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	8.9%
10% least volatile stocks in DK Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: BAVA hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: BAVA 'nin haftalık oynaklığı ( 9% ) geçen yıl boyunca sabit kaldı, ancak hala Danish hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1992	1,381	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S hayat kurtaran aşılar geliştirmekte, üretmekte ve ticarileştirmektedir. Şirket, IMVAMUNE, IMVANEX ve JYNNEOS adları altında çoğalmayan çiçek ve maymun çiçeği aşıları; Rabipur/RabAvert adı altında insan kullanımı için kuduz aşısı; Encepur adı altında kene kaynaklı ensefalit aşısı; ve MVABEA adı altında Ebola aşısı sunmaktadır. Ayrıca çiçek hastalığı tedavisi için MVA-BN; solunum sinsityal virüsü tedavisi için Faz III klinik çalışmalarında olan MVA-BN RSV; SARS-CoV-2 tedavisi için Faz III klinik çalışmasını tamamlayan ABNCoV2 geliştirmektedir.

Bavarian Nordic A/S Temel Bilgiler Özeti

Bavarian Nordic'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BAVA temel i̇stati̇sti̇kler
Piyasa değeri	DKK 17.05b
Kazançlar(TTM)	DKK 707.42m
Gelir(TTM)	DKK 6.08b

24.1x

F/K Oranı

2.8x

P/S Oranı

BAVA aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BAVA gelir tablosu (TTM)
Gelir	DKK 6.08b
Gelir Maliyeti	DKK 2.06b
Brüt Kâr	DKK 4.02b
Diğer Giderler	DKK 3.31b
Kazançlar	DKK 707.42m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 15, 2024

Hisse başına kazanç (EPS)	9.01
Brüt Marj	66.08%
Net Kâr Marjı	11.63%
Borç/Özkaynak Oranı	0.2%

BAVA uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

BAVA Stoklara Genel Bakış

Ödüller

Risk Analizi

Bavarian Nordic A/S Rakipler

CPSE:GMAB

DKK 99.3b

TSE:4587

JP¥382.4b

NasdaqCM:CPRX

US$2.5b

CPSE:ALK B

DKK 38.2b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Price target increased by 9.0% to kr.312

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

CEO & President exercised options to buy kr.24m worth of stock.

Recent updates

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Price target increased by 9.0% to kr.312

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

CEO & President exercised options to buy kr.24m worth of stock.

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Consensus EPS estimates increase by 56%

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher

Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models

Price target increased by 8.7% to kr.286

Second quarter 2024 earnings: Revenues exceed analyst expectations

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

New major risk - Share price stability

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Investor sentiment improves as stock rises 18%

Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Investor sentiment improves as stock rises 18%

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Deputy Chairman exercised options to buy kr.123k worth of stock.

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

CEO & President exercised options to buy kr.1.4m worth of stock.

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Price target increased by 9.4% to kr.293

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 15%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Consensus EPS estimates increase by 40%

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.